{"id":"buprenorphine-naloxone-drug-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Withdrawal symptoms (if inadequately dosed)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine's partial agonist activity at the mu-opioid receptor provides sufficient opioid effect to prevent withdrawal and reduce cravings, while its high receptor binding affinity blocks the euphoric effects of additional opioids. Naloxone, included in the combination, is a competitive opioid antagonist that becomes active if the combination is injected intravenously, discouraging intravenous abuse. Together, this combination provides safer opioid maintenance therapy with lower overdose risk compared to full mu-opioid agonists.","oneSentence":"Buprenorphine acts as a partial mu-opioid receptor agonist while naloxone acts as a mu-opioid receptor antagonist, together reducing opioid cravings and withdrawal symptoms while deterring misuse.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:10.947Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder maintenance treatment"},{"name":"Opioid dependence"}]},"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT04677114","phase":"PHASE2","title":"Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections","status":"COMPLETED","sponsor":"Laura Fanucchi","startDate":"2021-03-16","conditions":"Drug Use, Opioid-use Disorder","enrollment":71},{"nctId":"NCT07485335","phase":"PHASE4","title":"A Bundled Intervention - Phase 2","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-09-07","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":160},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT06367387","phase":"PHASE4","title":"Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erin Winstanley","startDate":"2024-05-28","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":268},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT04245423","phase":"NA","title":"The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-12-15","conditions":"Opioid-use Disorder, Mental Health Conditions","enrollment":567},{"nctId":"NCT03616236","phase":"PHASE3","title":"Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment","status":"SUSPENDED","sponsor":"Friends Research Institute, Inc.","startDate":"2022-07-01","conditions":"Opioid Use","enrollment":320},{"nctId":"NCT06306443","phase":"PHASE3","title":"Buprenorphine for Individuals in Jail","status":"RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2025-07-01","conditions":"Opioid Use Disorder","enrollment":240},{"nctId":"NCT05063201","phase":"PHASE2","title":"Cariprazine for Comorbid Cocaine and Opioid Use Disorder","status":"COMPLETED","sponsor":"Kyle Kampman","startDate":"2022-08-05","conditions":"Opioid-use Disorder, Cocaine Use Disorder","enrollment":26},{"nctId":"NCT04771689","phase":"PHASE4","title":"Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2022-07-01","conditions":"Post-operative Pain","enrollment":""},{"nctId":"NCT04375033","phase":"PHASE4","title":"A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-11-03","conditions":"Opioid Use Disorder","enrollment":952},{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT04091009","phase":"PHASE4","title":"Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-10","conditions":"Opioid-use Disorder, Opioid Use Disorder, Mild","enrollment":""},{"nctId":"NCT06023459","phase":"PHASE3","title":"Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yih-Ing Hser","startDate":"2024-10-14","conditions":"Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders","enrollment":144},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT04464421","phase":"NA","title":"SMART Effectiveness Trial","status":"COMPLETED","sponsor":"Karen Derefinko, PhD","startDate":"2020-08-17","conditions":"Opioid-use Disorder, Opioid Dependence, Treatment Adherence","enrollment":48},{"nctId":"NCT05118204","phase":"PHASE4","title":"Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2022-09-29","conditions":"Substance Use Disorders, Opioid-use Disorder, Chronic Pain","enrollment":23},{"nctId":"NCT04161066","phase":"PHASE1","title":"Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-01-13","conditions":"Opioid Use Disorder","enrollment":10},{"nctId":"NCT04600414","phase":"NA","title":"Collaborating to Heal Addiction and Mental Health in Primary Care","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-16","conditions":"Opioid-use Disorder, Mental Health Disorder","enrollment":254},{"nctId":"NCT04811014","phase":"PHASE4","title":"Young Houston Emergency Opioid Engagement System","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-04-19","conditions":"Opioid-use Disorder, Opioid Dependence, Opioid Overdose","enrollment":250},{"nctId":"NCT03396276","phase":"PHASE4","title":"Houston Emergency Opioid Engagement System","status":"ENROLLING_BY_INVITATION","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-01","conditions":"Opioid Use Disorder","enrollment":3000},{"nctId":"NCT05450718","phase":"PHASE4","title":"Low-dose Buprenorphine Initiation for Opioid Use Disorder","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-11-11","conditions":"Opioid Use Disorder","enrollment":70},{"nctId":"NCT05944952","phase":"PHASE4","title":"Low-dose Versus a High-dose Sublingual Buprenorphine Induction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2024-06-20","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT05976646","phase":"PHASE1, PHASE2","title":"Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2023-09-18","conditions":"Addiction, Opioid Use, Substance Use Disorders","enrollment":18},{"nctId":"NCT04948307","phase":"NA","title":"OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2021-06-30","conditions":"Opioid-use Disorder","enrollment":437},{"nctId":"NCT03918850","phase":"PHASE3","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":140},{"nctId":"NCT04893525","phase":"PHASE2, PHASE3","title":"Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-07-23","conditions":"Opioid-use Disorder","enrollment":658},{"nctId":"NCT05011266","phase":"PHASE2, PHASE3","title":"Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2023-04-18","conditions":"Opioid-use Disorder","enrollment":180},{"nctId":"NCT06494904","phase":"PHASE3","title":"Standard Versus High Dose ED-Initiated Buprenorphine Induction","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-12-06","conditions":"Opioid Use Disorder","enrollment":360},{"nctId":"NCT06406400","phase":"PHASE1","title":"Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-05-13","conditions":"Opioid Use Disorder","enrollment":15},{"nctId":"NCT03993392","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-08-29","conditions":"Opioid-use Disorder","enrollment":26},{"nctId":"NCT04080180","phase":"NA","title":"SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence","status":"COMPLETED","sponsor":"Karen Derefinko, PhD","startDate":"2022-02-01","conditions":"Opioid-use Disorder","enrollment":332},{"nctId":"NCT04447287","phase":"PHASE1","title":"A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-06-29","conditions":"Opioid Use Disorder","enrollment":23},{"nctId":"NCT04818086","phase":"PHASE1, PHASE2","title":"Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2021-05-03","conditions":"Drug Interaction, Analgesics, Opioid Use Disorder","enrollment":18},{"nctId":"NCT04737603","phase":"PHASE2","title":"Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Davis","startDate":"2025-07-30","conditions":"Opioid-use Disorder","enrollment":""},{"nctId":"NCT05062577","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-11-08","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT03718104","phase":"","title":"MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2018-12-01","conditions":"Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk","enrollment":46},{"nctId":"NCT04253782","phase":"NA","title":"SafetyNet Program for Opioid Use Disorder (OUD)","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-07-01","conditions":"Opioid-Use Disorder (OUD)","enrollment":81},{"nctId":"NCT03908437","phase":"PHASE4","title":"Rapid Initiation of Drug Treatment Engagement","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-07-15","conditions":"Opioid-use Disorder, Overdose","enrollment":104},{"nctId":"NCT04976855","phase":"PHASE1","title":"Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2022-08-17","conditions":"Healthy Volunteer, Opioid-use Disorder","enrollment":64},{"nctId":"NCT05644587","phase":"PHASE4","title":"Novel Induction to Buprenorphine/Naloxone","status":"TERMINATED","sponsor":"Bicycle Health","startDate":"2023-02-06","conditions":"Opioid Use Disorder, Opioid Use, Opioid Abuse","enrollment":33},{"nctId":"NCT04480554","phase":"PHASE2","title":"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-30","conditions":"Opioid-use Disorder, HIV-1-infection, Immune Activation","enrollment":225},{"nctId":"NCT04234191","phase":"PHASE2","title":"Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-08-18","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT04794790","phase":"EARLY_PHASE1","title":"Buprenorphine Induction for Fentanyl Dependent Opioid Users","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-05-09","conditions":"Opioid Dependence Fentanyl","enrollment":""},{"nctId":"NCT04283500","phase":"PHASE4","title":"Buprenorphine Loading in the Emergency Department","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-11-01","conditions":"Opioid-use Disorder","enrollment":15},{"nctId":"NCT03291847","phase":"PHASE2","title":"Maternal Buprenorphine-naloxone Treatment and the Infant","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-06-01","conditions":"Maternal Opioid Use Disorder, Opioid Exposed Infant","enrollment":42},{"nctId":"NCT04049799","phase":"","title":"Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2019-08-08","conditions":"Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome","enrollment":88},{"nctId":"NCT05164549","phase":"PHASE3","title":"Extended-release Pharmacotherapy for Opioid Use Disorder","status":"COMPLETED","sponsor":"King's College London","startDate":"2019-08-06","conditions":"Opiate Substitution Treatment","enrollment":342},{"nctId":"NCT03976258","phase":"","title":"Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2017-07-14","conditions":"HIV Infection, Opioid-use Disorder, Cardiovascular Diseases","enrollment":190},{"nctId":"NCT04521920","phase":"NA","title":"Providing Suboxone and PrEP Using Telemedicine","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-11-09","conditions":"Opioid Use, Opioid-use Disorder, Risk Reduction","enrollment":17},{"nctId":"NCT01843751","phase":"PHASE3","title":"Dane County Drug Court Study for Addicted Offenders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2013-03","conditions":"Opioid Dependence","enrollment":24},{"nctId":"NCT01082679","phase":"PHASE2, PHASE3","title":"Treatment for Opioid Dependent Offenders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-06","conditions":"Opioid Dependence","enrollment":16},{"nctId":"NCT03026790","phase":"PHASE2","title":"Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2017-10-19","conditions":"Chronic Pain","enrollment":820},{"nctId":"NCT05307458","phase":"","title":"Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing","status":"UNKNOWN","sponsor":"United Health Services Hospitals, Inc.","startDate":"2022-07-01","conditions":"Opioid Use Disorder, Opioid Withdrawal","enrollment":20},{"nctId":"NCT05108935","phase":"NA","title":"Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP","status":"COMPLETED","sponsor":"Duke University","startDate":"2022-02-17","conditions":"Opioid Use, Opioid Use Disorder, Risk Reduction","enrollment":17},{"nctId":"NCT04991974","phase":"PHASE2, PHASE3","title":"Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine","status":"UNKNOWN","sponsor":"Friends Research Institute, Inc.","startDate":"2021-09-17","conditions":"Opioid-use Disorder","enrollment":360},{"nctId":"NCT00684073","phase":"PHASE4","title":"Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2007-07","conditions":"Opiate-related Disorders, Opiate Dependence, Drug Abuse","enrollment":60},{"nctId":"NCT04656899","phase":"NA","title":"Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Phase I Study","status":"COMPLETED","sponsor":"Washington State University","startDate":"2020-12-06","conditions":"Opioid-use Disorder","enrollment":41},{"nctId":"NCT02187198","phase":"PHASE3","title":"Buprenorphine Treatment for Opioid Dependence","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-03","conditions":"Opioid Dependence","enrollment":9},{"nctId":"NCT05179772","phase":"PHASE2","title":"Olanzapine in OUD Patients","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2022-07-28","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT03580902","phase":"PHASE1, PHASE2","title":"CBT4CBT for Office Based Buprenorphine","status":"COMPLETED","sponsor":"CBT4CBT, LLC","startDate":"2019-01-22","conditions":"Opioid-use Disorder","enrollment":51},{"nctId":"NCT03711318","phase":"PHASE3","title":"Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2018-11-01","conditions":"Heroin Dependence","enrollment":8},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT04139213","phase":"PHASE2, PHASE3","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"UNKNOWN","sponsor":"Lifespan","startDate":"2019-07-25","conditions":"Opioid-use Disorder","enrollment":250},{"nctId":"NCT02696096","phase":"PHASE3","title":"Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence","status":"COMPLETED","sponsor":"Butler Hospital","startDate":"2016-08","conditions":"Opioid Addiction","enrollment":21},{"nctId":"NCT03658642","phase":"NA","title":"Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-11-15","conditions":"Clinical Decision Support, Buprenorphine, Opioid-use Disorder","enrollment":5047},{"nctId":"NCT03744663","phase":"PHASE2","title":"Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2022-06","conditions":"Opioid Use","enrollment":""},{"nctId":"NCT00929253","phase":"NA","title":"Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2007-09","conditions":"Opiate Addiction","enrollment":170},{"nctId":"NCT01936857","phase":"PHASE4","title":"Buprenorphine to Improve HIV Care Engagement and Outcomes","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2015-07","conditions":"HIV, Substance Related Disorders","enrollment":281},{"nctId":"NCT05368675","phase":"PHASE4","title":"Medication-assisted Treatment for Injecting Drug Users in Vietnam","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-12-18","conditions":"Opioid Use Disorder, HIV Infections","enrollment":448},{"nctId":"NCT03492099","phase":"PHASE2","title":"Assessing the Safety of Buprenorphine in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-08-01","conditions":"Sickle Cell Disease","enrollment":47},{"nctId":"NCT03604159","phase":"PHASE4","title":"XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-24","conditions":"Opioid Dependence","enrollment":52},{"nctId":"NCT04449744","phase":"NA","title":"Evaluating Adaptive Dispenser Initiation Protocols for MySafeRx During Post-detox Buprenorphine Treatment- a Pilot Study","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2020-07-13","conditions":"Opioid-use Disorder","enrollment":19},{"nctId":"NCT01843023","phase":"PHASE4","title":"Extended Release Naltrexone for Opioid-Dependent Youth","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2013-06","conditions":"Drug Dependence","enrollment":288},{"nctId":"NCT00270257","phase":"PHASE3","title":"Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Opioid-Related Disorders","enrollment":1251},{"nctId":"NCT01402492","phase":"PHASE2, PHASE3","title":"Cocaine Use Reduction With Buprenorphine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-09","conditions":"Cocaine Dependence","enrollment":302},{"nctId":"NCT02778282","phase":"NA","title":"MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2017-03-24","conditions":"Opioid Use Disorder","enrollment":27},{"nctId":"NCT00634803","phase":"PHASE1, PHASE2","title":"Clinical Trial of Integrated Treatment for Pain and Opioid Dependence","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-09","conditions":"Opiate Dependence, Chronic Pain","enrollment":90},{"nctId":"NCT03248947","phase":"EARLY_PHASE1","title":"Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-03-28","conditions":"Opioid Use Disorder","enrollment":71},{"nctId":"NCT00539123","phase":"NA","title":"Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-09","conditions":"Opiate Dependence","enrollment":234},{"nctId":"NCT04234516","phase":"PHASE4","title":"Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2020-01-20","conditions":"Opioid-use Disorder, Suicidal Ideation","enrollment":""},{"nctId":"NCT03033732","phase":"PHASE4","title":"A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse","status":"COMPLETED","sponsor":"Didier Jutras Aswad","startDate":"2017-10-02","conditions":"Opioid Use Disorder","enrollment":272},{"nctId":"NCT03235154","phase":"PHASE4","title":"A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2017-10-11","conditions":"Hepatitis C, Chronic, Hepatitis C, Opiate Dependence","enrollment":11},{"nctId":"NCT03015246","phase":"PHASE1, PHASE2","title":"Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2016-12","conditions":"Heroin Dependence, Opioid Use Disorder","enrollment":26},{"nctId":"NCT01559454","phase":"PHASE4","title":"Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2012-02","conditions":"Low Back Pain","enrollment":19},{"nctId":"NCT03968237","phase":"","title":"Measures to Improve Outcomes After an Opioid Overdose","status":"UNKNOWN","sponsor":"Nassima Ait-Daoud Tiouririne","startDate":"2019-08-01","conditions":"Opioid Overdose","enrollment":200},{"nctId":"NCT04212065","phase":"PHASE4","title":"Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women","status":"WITHDRAWN","sponsor":"Ohio State University","startDate":"2020-02-21","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT02032433","phase":"PHASE4","title":"Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-01-29","conditions":"Opioid Use Disorder","enrollment":570},{"nctId":"NCT03287180","phase":"NA","title":"Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2019-01-01","conditions":"Opioid-Related Disorders, Behavior, Addictive","enrollment":""},{"nctId":"NCT02526212","phase":"PHASE3","title":"Buprenorphine Group Medical Visits in Primary Care","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2017-01-01","conditions":"Opioid-Related Disorders","enrollment":18},{"nctId":"NCT03583138","phase":"","title":"HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-06-23","conditions":"Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction","enrollment":159},{"nctId":"NCT01550341","phase":"NA","title":"HIV, Buprenorphine, and the Criminal Justice System","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-02-23","conditions":"Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction","enrollment":50},{"nctId":"NCT00486330","phase":"NA","title":"Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-05","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00595764","phase":"PHASE4","title":"Counseling for Primary Care Office-based Buprenorphine","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-08","conditions":"Opiate Dependence","enrollment":141},{"nctId":"NCT03740243","phase":"PHASE4","title":"Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology","status":"WITHDRAWN","sponsor":"Stony Brook University","startDate":"2018-11-30","conditions":"Opioid-use Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Suboxone"],"phase":"marketed","status":"active","brandName":"Buprenorphine, Naloxone Drug Combination","genericName":"Buprenorphine, Naloxone Drug Combination","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine acts as a partial mu-opioid receptor agonist while naloxone acts as a mu-opioid receptor antagonist, together reducing opioid cravings and withdrawal symptoms while deterring misuse. Used for Opioid use disorder maintenance treatment, Opioid dependence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}